

Recommendations for the Prescribing of Lubiprostone

Summary

Lubiprostone is recommended as a treatment option for treating chronic idiopathic constipation, that is for adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment is being considered.

It is recommended for initiation by primary or secondary care in accordance with the treatment pathway outlined below.

NICE issued TA 138 in July 2014 with the following recommendations for the use of lubiprostone:

1.1 Lubiprostone is recommended as an option for treating chronic idiopathic constipation, that is, for adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered.

1.2 If treatment with lubiprostone is not effective after 2 weeks, the person should be re-examined and the benefit of continuing treatment reconsidered.

1.3 Lubiprostone should only be prescribed by a clinician with experience of treating chronic idiopathic constipation, who has carefully reviewed the person's previous courses of laxative treatments specified in 1.1

Comparative Treatments

The only comparative treatment is prucalopride which has the same NICE recommendation as above, except that it is only licensed for use in women. The recommended trial of treatment is 4 weeks as opposed to 2 weeks for lubiprostone.

- Lubiprostone has a different mechanism of action to prucalopride, as it activates chloride channels in gastrointestinal epithelial cells, relieving symptoms of chronic constipation by improving intestinal secretion.
- Prucalopride is a selective serotonin 5HT₄ receptor agonist with prokinetic properties.

Drug	Dose	Cost for 28 dys
Lubiprostone	24mcg bd	£53.48
	24mcg od (mod - severe hepatic impairment)	£29.68
Prucalopride	1mg daily (over 65 yrs starting dose)	£38.69
	2mg daily	£59.52

Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal CCG, South Kent Coast CCG and Thanet CCG)


Date: October 2014

Address: Medicine Management, 81 Station Road, Ashford, Kent, TN23 1PP

Contact: T: 01233 618140 | F: 01233 618195 | E: medman.eck@nhs.net

Integrated Care Pathway for Chronic Idiopathic Constipation

Not to be used in <18years of age or in pregnancy



The information is issued for guidance and advice only. Always read the full summary of Product Characteristics for any drug or class of drug mentioned.

Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal CCG, South Kent Coast CCG and Thanet CCG)

Date: October 2014

Address: c/o Canterbury and Coastal CCG, Council Offices, Military Road, Canterbury, CT1 1YW

Contact: T: 01227 791359 | E: accg.eastkent.prescribing@nhs.net